The HTLV assay, developed in partnership with Avioq, is designed to screen blood and organ donations for antibodies to human T-lymphotropic virus (HTLV) type I and II.

The company said the assay is fully compatible with the Ortho summit system platform which reduces validation time and assay variation, while improving productivity in the lab.

Ortho Clinical Diagnostics principle scientist Paul Contestable said by providing a reliable screening method for antibodies to HTLV type I and II, the company is enhancing the donor screening community’s ability to adhere to the FDA’s testing guidelines, while at the same time protect patients who receive blood and plasma donations.